PEPTIDE Registry

Reported experiences and published evidence, kept separate. Explore what people seek, what sources actually study and what remains unknown.

Collection closed. No participant results published.

What would you like to explore?

All groups and topics

Reported-use topics, not evidence grades or diagnoses. The catalog does not cover every possible experience.

Elamipretide / SS-31

Editorial context from existing sources; independent scientific review pending. Numerical findings held. A reported-use topic does not establish direct evidence for that aim.

Forzinity received a narrow US accelerated approval in 2025 for muscle strength in Barth syndrome in patients meeting the labeled weight threshold.

The small study and approval conditions matter. This is not approval for general fatigue, anti-aging, athletic optimization or every research-grade SS-31 vial. FDA’s trial snapshot reports that the randomized primary endpoints were not superior to placebo; strength increases were observed during the extension.

Sources and proposed-mechanism explanation

Mitochondrial membrane biology explains research interest. “Mitochondrial support” must be translated into a defined patient outcome.

Practice & Evidence: claims and limits

Collection, review and methods

8 documents · 24 educational profiles · 10 guides. Hosting authorization and reviews remain pending. Drafts are not reports; they do not establish effectiveness or safety.

Methods, consent and privacy

Understanding community practices What each evidence label means Stacks, mixtures and claims of synergy How we handle reported doses and cycles Reading a peptide quality report When someone says it worked Source errors, corrections and retractions From experience to a research question The proposed Community Observation Program Reading future observational results